Trial Outcomes & Findings for Text Intervention to Facilitate Secure Storage and Disposal of Prescription Opioids (NCT NCT05503186)
NCT ID: NCT05503186
Last Updated: 2026-04-22
Results Overview
Investigators will assess the differences in the percentage of participants who securely stored their opioid medication during treatment using a dichotomous, close-ended question on a self-administered questionnaire.
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
479 participants
Primary outcome timeframe
45 days following enrollment
Results posted on
2026-04-22
Participant Flow
We used a multimethod approach to recruitment. Potential participants who were recently prescribed opioid medication were identified through Electronic Health Records (EHR) and sent a single message in their MyChart inviting them to participate. We also posted flyers in local pharmacies with study information. Participants were directed to an online consent form programmed in REDCap®. If the participant consented to participate, they completed the self-directed web-based eligibility screener.
If eligible, they transitioned immediately from the screening questions to the baseline survey. Following completion of the baseline survey, the participant was randomized to study condition using simple randomization procedures with stratification by biological sex.
Participant milestones
| Measure |
Text Message Intervention Study Condition
The intervention is a text message intervention. Text messages will provide guidance on secure storage and disposal of prescription opioids to participants who have been dispensed a prescription opioid. Participants in the intervention study condition will receive a series of text messages that aim to facilitate secure storage and disposal of unused opioid prescriptions.
|
Control Study Condition
Participants assigned to the control study condition will not receive the text message intervention. Participants assigned to the control study condition will receive a standard of care of treatment which is whatever guidance that is provided to them by their physician and/or pharmacist.
|
|---|---|---|
|
Overall Study
STARTED
|
244
|
235
|
|
Overall Study
COMPLETED
|
188
|
210
|
|
Overall Study
NOT COMPLETED
|
56
|
25
|
Reasons for withdrawal
| Measure |
Text Message Intervention Study Condition
The intervention is a text message intervention. Text messages will provide guidance on secure storage and disposal of prescription opioids to participants who have been dispensed a prescription opioid. Participants in the intervention study condition will receive a series of text messages that aim to facilitate secure storage and disposal of unused opioid prescriptions.
|
Control Study Condition
Participants assigned to the control study condition will not receive the text message intervention. Participants assigned to the control study condition will receive a standard of care of treatment which is whatever guidance that is provided to them by their physician and/or pharmacist.
|
|---|---|---|
|
Overall Study
Withdrawal by Subject
|
6
|
2
|
|
Overall Study
Completed but not included in analysis due to technical error
|
50
|
23
|
Baseline Characteristics
Text Intervention to Facilitate Secure Storage and Disposal of Prescription Opioids
Baseline characteristics by cohort
| Measure |
Text Message Intervention Study Condition
n=188 Participants
The intervention is a text message intervention. Text messages will provide guidance on secure storage and disposal of prescription opioids to participants who have been dispensed a prescription opioid. Participants in the intervention study condition will receive a series of text messages that aim to facilitate secure storage and disposal of unused opioid prescriptions.
|
Control Study Condition
n=210 Participants
Participants assigned to the control study condition will not receive the text message intervention. Participants assigned to the control study condition will receive a standard of care of treatment which is whatever guidance that is provided to them by their physician and/or pharmacist.
|
Total
n=398 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Age, Customized
18-25 years
|
15 Participants
n=60 Participants
|
9 Participants
n=56 Participants
|
24 Participants
n=116 Participants
|
|
Age, Customized
26-35 years
|
31 Participants
n=60 Participants
|
40 Participants
n=56 Participants
|
71 Participants
n=116 Participants
|
|
Age, Customized
36-45 years
|
34 Participants
n=60 Participants
|
47 Participants
n=56 Participants
|
81 Participants
n=116 Participants
|
|
Age, Customized
45-55 years
|
52 Participants
n=60 Participants
|
45 Participants
n=56 Participants
|
97 Participants
n=116 Participants
|
|
Age, Customized
56-65 years
|
30 Participants
n=60 Participants
|
33 Participants
n=56 Participants
|
63 Participants
n=116 Participants
|
|
Age, Customized
66-75 years
|
18 Participants
n=60 Participants
|
22 Participants
n=56 Participants
|
40 Participants
n=116 Participants
|
|
Age, Customized
76+ years
|
8 Participants
n=60 Participants
|
14 Participants
n=56 Participants
|
22 Participants
n=116 Participants
|
|
Sex: Female, Male
Female
|
134 Participants
n=60 Participants
|
140 Participants
n=56 Participants
|
274 Participants
n=116 Participants
|
|
Sex: Female, Male
Male
|
54 Participants
n=60 Participants
|
70 Participants
n=56 Participants
|
124 Participants
n=116 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
2 Participants
n=60 Participants
|
1 Participants
n=56 Participants
|
3 Participants
n=116 Participants
|
|
Race (NIH/OMB)
Asian
|
3 Participants
n=60 Participants
|
1 Participants
n=56 Participants
|
4 Participants
n=116 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=60 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=116 Participants
|
|
Race (NIH/OMB)
Black or African American
|
25 Participants
n=60 Participants
|
40 Participants
n=56 Participants
|
65 Participants
n=116 Participants
|
|
Race (NIH/OMB)
White
|
152 Participants
n=60 Participants
|
165 Participants
n=56 Participants
|
317 Participants
n=116 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=60 Participants
|
0 Participants
n=56 Participants
|
0 Participants
n=116 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
6 Participants
n=60 Participants
|
3 Participants
n=56 Participants
|
9 Participants
n=116 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
7 Participants
n=60 Participants
|
8 Participants
n=56 Participants
|
15 Participants
n=116 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
176 Participants
n=60 Participants
|
198 Participants
n=56 Participants
|
374 Participants
n=116 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
5 Participants
n=60 Participants
|
4 Participants
n=56 Participants
|
9 Participants
n=116 Participants
|
PRIMARY outcome
Timeframe: 45 days following enrollmentPopulation: We excluded participants who did not have outcome data.
Investigators will assess the differences in the percentage of participants who securely stored their opioid medication during treatment using a dichotomous, close-ended question on a self-administered questionnaire.
Outcome measures
| Measure |
Text Message Intervention Study Condition
n=188 Participants
The intervention is a text message intervention. Text messages will provide guidance on secure storage and disposal of prescription opioids to participants who have been dispensed a prescription opioid. Participants in the intervention study condition will receive a series of text messages that aim to facilitate secure storage and disposal of unused opioid prescriptions.
|
Control Study Condition
n=210 Participants
Participants assigned to the control study condition will not receive the text message intervention. Participants assigned to the control study condition will receive a standard of care of treatment which is whatever guidance that is provided to them by their physician and/or pharmacist.
|
|---|---|---|
|
Percentage of Participants Who Securely Stored Their Opioid Medication During Treatment
Participants who stored their medication in a locked location
|
48 Participants
|
29 Participants
|
|
Percentage of Participants Who Securely Stored Their Opioid Medication During Treatment
Participants who did not store their medication in a locked location
|
140 Participants
|
181 Participants
|
PRIMARY outcome
Timeframe: 45 days following enrollmentPopulation: We excluded participants who did not have outcome data and who used all of their opioid medication.
Investigators will assess the differences in the percentage of participants who disposed of their unused opioid medication following completion of treatment using a dichotomous, close-ended question on a self-administered questionnaire.
Outcome measures
| Measure |
Text Message Intervention Study Condition
n=97 Participants
The intervention is a text message intervention. Text messages will provide guidance on secure storage and disposal of prescription opioids to participants who have been dispensed a prescription opioid. Participants in the intervention study condition will receive a series of text messages that aim to facilitate secure storage and disposal of unused opioid prescriptions.
|
Control Study Condition
n=100 Participants
Participants assigned to the control study condition will not receive the text message intervention. Participants assigned to the control study condition will receive a standard of care of treatment which is whatever guidance that is provided to them by their physician and/or pharmacist.
|
|---|---|---|
|
Percentage of Participants Who Disposed of Their Unused Opioid Medication
Disposed of unused medication
|
21 Participants
|
12 Participants
|
|
Percentage of Participants Who Disposed of Their Unused Opioid Medication
Did not dispose of unused medication
|
76 Participants
|
88 Participants
|
Adverse Events
Text Message Intervention Study Condition
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Control Study Condition
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Kathleen Egan
Wake Forest University School of Medicine
Phone: 704-355-2000
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place